We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+50.65%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.42B
AUM Growth
+$1.85B
Cap. Flow
+$509M
Cap. Flow %
9.4%
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9

Top Buys

Rank Stock Value
1
ADCT icon
ADC Therapeutics
ADCT
+$210M
2
BNTX icon
BioNTech
BNTX
+$145M
3
IMMU
Immunomedics Inc
IMMU
+$102M
4
PLRX icon
Pliant Therapeutics
PLRX
+$90.5M
5
RPTX
Repare Therapeutics
RPTX
+$76.6M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$128M
2
QURE icon
uniQure
QURE
+$90.1M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$75.7M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$56.7M
5
CNC icon
Centene
CNC
+$49M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Industrials 1.02%
3 Financials 0.23%
4 Miscellaneous 0.16%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAH
51
DELISTED
PRA Health Sciences, Inc.
PRAH
$27.2M 0.5%
279,336
-163,364
-37% -$15.2M
TCRR
52
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$27.1M 0.5%
1,765,188
-2,100
-0.1% -$24.2K
ODT
53
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$26.8M 0.49%
633,038
-75,000
-11% -$2.43M
TWST icon
54
Twist Bioscience
TWST
$8.87B
$26.7M 0.49%
589,300
-900
-0.2% -$32.3K
CLDX icon
55
Celldex Therapeutics
CLDX
$3.07B
$26M 0.48%
+2,000,000
New +$8.86M
ARDX icon
56
Ardelyx
ARDX
$984M
$24.3M 0.45%
3,514,100
-390,000
-10% -$2.71M
GH icon
57
Guardant Health
GH
$21.7B
$24.1M 0.45%
+297,619
New +$24M
HOOK
58
DELISTED
HOOKIPA Pharma
HOOK
$21.6M 0.4%
186,061
-190
-0.1% -$18.5K
BCEL
59
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$21.1M 0.39%
992,068
-136,738
-12% -$2.42M
GRTS
60
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$20.4M 0.38%
3,064,994
-3,200
-0.1% -$21.6K
CABA icon
61
Cabaletta Bio
CABA
$529M
$15.9M 0.29%
1,425,896
– –
IMVT icon
62
Immunovant
IMVT
$8.51B
$14.6M 0.27%
+600,000
New +$12.9M
STXS icon
63
Stereotaxis
STXS
$145M
$13.8M 0.26%
3,103,327
– –
NVTA
64
DELISTED
Invitae Corporation
NVTA
$13.1M 0.24%
+431,100
New +$7.52M
SLQT icon
65
SelectQuote
SLQT
$91.8M
$12.6M 0.23%
+496,872
New +$13.3M
ITMR
66
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$11.6M 0.21%
625,000
– –
AKRO
67
DELISTED
Akero Therapeutics
AKRO
$9.77M 0.18%
392,152
-177,361
-31% -$4.05M
RPRX icon
68
Royalty Pharma
RPRX
$27.1B
$9.71M 0.18%
+200,000
New +$9.9M
BMY.RT
69
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$8.83M 0.16%
2,467,000
+78,000
+3% +$281K
PROF
70
Profound Medical
PROF
$250M
$6.78M 0.13%
400,000
– –
AYLA
71
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$6.69M 0.12%
+666,666
New +$9.26M
XERS icon
72
Xeris Biopharma Holdings
XERS
$1.55B
$6.38M 0.12%
2,397,441
-560,000
-19% -$1.95M
CBAY
73
DELISTED
Cymabay Therapeutics
CBAY
$5.84M 0.11%
1,674,447
-1,076,169
-39% -$3.11M
WVE icon
74
Wave Life Sciences
WVE
$993M
$4.32M 0.08%
415,155
-2,512,197
-86% -$23.6M
BNR
75
Burning Rock Biotech
BNR
$107M
$3.62M 0.07%
+13,393
New +$3.67M
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2020 Portfolio in Review

As of Q2 2020, Redmile Group held 89 positions worth $5.42B, up 52% from $3.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $509M of net new capital in Q2 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was ADC Therapeutics: 5,525,870 shares worth $259M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Biogen, an estimated $128M trimmed.

  • Redmile Group's largest Q2 2020 buy was ADC Therapeutics: 5,525,870 shares worth $259M.
  • Redmile Group added most to BioNTech in Q2 2020, an estimated $145M increase.
  • Redmile Group's biggest Q2 2020 reduction was Biogen, cutting an estimated $128M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q2 2020, selling an estimated $75.7M.
  • Redmile Group's ten largest holdings make up 47% of its $5.42B portfolio in Q2 2020.
  • Redmile Group opened 20 new positions and closed 9 in Q2 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $5.42B.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.